Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Dance-501(Dance Biopharm Holdings, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Dance-501(Dance Biopharm Holdings, Inc.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bevacizumab-IRDye800CW(University of Groningen) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Bevacizumab-IRDye800CW(University of Groningen): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Terbium-161 DOTATATE Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Terbium-161 DOTATATE: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lixudebart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Lixudebart: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Mitoglitazone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Mitoglitazone: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Zotatifin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Zotatifin: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Leiolizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Leiolizumab: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Disitertide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Disitertide: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Brogidirsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Brogidirsen: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Menadiol Sodium Diphosphate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Menadiol Sodium Diphosphate: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lithium Citrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Lithium Citrate: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Quinolicin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Quinolicin: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.